<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00569114</url>
  </required_header>
  <id_info>
    <org_study_id>TP2001-101</org_study_id>
    <nct_id>NCT00569114</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients</brief_title>
  <official_title>A Phase 1 Dose-Escalation Pharmacokinetic and Pharmacodynamic Study of TG01 Tablets in Combination With Erlotinib in Non-Small Cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tragara Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tragara Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, phase 1, dose escalation study. The purpose is to
      determine the highest dose of TG01 that can be safely given to patients with Non-Small Cell
      Lung Cancer in combination with erlotinib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Saftey, maximum tolerated dose, optimal biological dose and pharmacokinetics.</measure>
    <time_frame>Baseline, 8, 15 and 28 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TG01</intervention_name>
    <description>Drug:TG01tablets given orally QD Drug: erlotinib tablets 150mg QD</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (include but are not limited to):

          -  Histogically or pathologically determined relapsed/recurrent Stage IIIb (plueral
             effusion) or IV NSCLC.

          -  Measurable or evaluable disease as defined by RECIST

          -  Must have failed at least one prior chemotherapy regimen or have refused chemotherapy.

          -  ECOG perfromance status of 0,1, or 2.

        Exclusion Criteria (include but are not limited to):

          -  Radiation therapy (excluding CNS therapy) &lt; 2 weeks, chemotherapy, non-cytotoxic
             investigational agents or high dose corticosteroids within 3 weeks of intitating
             therpy or patients who have not recovered from adverse effects due to agents
             administered more than 3 weeks earlier.

          -  Evidence of New York Heart Associatation Class III or greater cardiac disease.

          -  History of myocardial infarction, stroke, or cardiovascular intervention within the
             last 12 months.

          -  Patients on anti-platlet drugs or anticoagulants such as Placix and Coumadin.

          -  Systemic central nervous system metastases. The patient must be stable after
             radiotherapy for &gt;/= to 2 weeks and off corticosteroids for &gt;/= to 1 week.

          -  Pregnant or nursing women.

          -  Patients who are primarily refactory to erlotinib.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Zaknoen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tragara Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Blood and Cancer Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2007</study_first_submitted>
  <study_first_submitted_qc>December 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <last_update_submitted>March 16, 2010</last_update_submitted>
  <last_update_submitted_qc>March 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sara Zaknoen, MD</name_title>
    <organization>Tragara Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

